Ruby Singh

Bio

Dr. Ruby Singh is a senior regulatory microbiologist at the Center for Veterinary medicine, U.S. Food and Drug Administration (FDA). Dr. Singh’s area of expertise is in regulatory policies aimed at assessing the relationships between antimicrobial uses in veterinary medicine and the potential consequences to human health. Dr. Singh works very closely with the regulated pharmaceutical industry, other government agencies, academia, and the public by helping develop policies and guidelines on mitigating foodborne antimicrobial resistance (AMR) risks to humans, including the development and implementation of strategies to improve food safety, and stewardship of antimicrobial drug use in veterinary medicine – a goal that is aligned with the global One Health resistome challenge. In addition, her current work includes the pre-approval review of complex qualitative food safety risk assessments for antimicrobials intended for use in food producing animals. Dr. Singh is currently the lead on revising FDA’s list of medically important antimicrobials, and a member of the WHO advisory group on the Critically Important List of Antimicrobials for human medicine. She has also been a U.S. government representative to the Codex Task Force on AMR, the Transatlantic task force on AMR and the U.S. National action plan on Combating Resistance Bacteria. Dr. Singh has also served as a past expert on the WHO Advisory group on integrated surveillance of AMR (AGISAR).